Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

Ataru Igarashi; Emi Hirose; Yasuhiro Kobayashi; Naohiro Yonemoto; Bennett Lee

doi:10.1080/14760584.2022.2036129

Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

Ataru Igarashi, Emi Hirose^*, Yasuhiro Kobayashi, Naohiro Yonemoto, Bennett Lee

^*Corresponding author for this work

Department of Biostatistics

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	591-592
Number of pages	2
Journal	Expert Review of Vaccines
Volume	21
Issue number	5
DOIs	https://doi.org/10.1080/14760584.2022.2036129
State	Published - 2022

ASJC Scopus subject areas

Immunology
Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1080/14760584.2022.2036129

Cite this

Igarashi, A., Hirose, E., Kobayashi, Y., Yonemoto, N., & Lee, B. (2022). Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Review of Vaccines, 21(5), 591-592. https://doi.org/10.1080/14760584.2022.2036129

@article{8ba6051089394ad4bd6e7832217b5df4,

title = "Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan",

author = "Ataru Igarashi and Emi Hirose and Yasuhiro Kobayashi and Naohiro Yonemoto and Bennett Lee",

year = "2022",

doi = "10.1080/14760584.2022.2036129",

language = "英語",

volume = "21",

pages = "591--592",

journal = "Expert Review of Vaccines",

issn = "1476-0584",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

Igarashi, A, Hirose, E, Kobayashi, Y, Yonemoto, N & Lee, B 2022, 'Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan', Expert Review of Vaccines, vol. 21, no. 5, pp. 591-592. https://doi.org/10.1080/14760584.2022.2036129

Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. / Igarashi, Ataru; Hirose, Emi; Kobayashi, Yasuhiro et al.
In: Expert Review of Vaccines, Vol. 21, No. 5, 2022, p. 591-592.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

AU - Igarashi, Ataru

AU - Hirose, Emi

AU - Kobayashi, Yasuhiro

AU - Yonemoto, Naohiro

AU - Lee, Bennett

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85125348161&partnerID=8YFLogxK

U2 - 10.1080/14760584.2022.2036129

DO - 10.1080/14760584.2022.2036129

M3 - Letter

C2 - 35104176

AN - SCOPUS:85125348161

SN - 1476-0584

VL - 21

SP - 591

EP - 592

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

IS - 5

ER -